164 related articles for article (PubMed ID: 32511378)
1. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.
Ma C; Sacco MD; Hurst B; Townsend JA; Hu Y; Szeto T; Zhang X; Tarbet B; Marty MT; Chen Y; Wang J
bioRxiv; 2020 Jan; ():. PubMed ID: 32511378
[TBL] [Abstract][Full Text] [Related]
2. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.
Ma C; Sacco MD; Hurst B; Townsend JA; Hu Y; Szeto T; Zhang X; Tarbet B; Marty MT; Chen Y; Wang J
Cell Res; 2020 Aug; 30(8):678-692. PubMed ID: 32541865
[TBL] [Abstract][Full Text] [Related]
3. Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses.
Hu Y; Ma C; Szeto T; Hurst B; Tarbet B; Wang J
ACS Infect Dis; 2021 Mar; 7(3):586-597. PubMed ID: 33645977
[TBL] [Abstract][Full Text] [Related]
4. Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture.
Hu Y; Ma C; Szeto T; Hurst B; Tarbet B; Wang J
bioRxiv; 2020 Nov; ():. PubMed ID: 33140049
[TBL] [Abstract][Full Text] [Related]
5. Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against M
Sacco MD; Ma C; Lagarias P; Gao A; Townsend JA; Meng X; Dube P; Zhang X; Hu Y; Kitamura N; Hurst B; Tarbet B; Marty MT; Kolocouris A; Xiang Y; Chen Y; Wang J
bioRxiv; 2020 Jul; ():. PubMed ID: 32766590
[TBL] [Abstract][Full Text] [Related]
6. Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir.
Xia Z; Sacco M; Hu Y; Ma C; Meng X; Zhang F; Szeto T; Xiang Y; Chen Y; Wang J
ACS Pharmacol Transl Sci; 2021 Aug; 4(4):1408-1421. PubMed ID: 34414360
[TBL] [Abstract][Full Text] [Related]
7. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
8. Identification of highly effective inhibitors against SARS-CoV-2 main protease: From virtual screening to in vitro study.
Wang H; Wen J; Yang Y; Liu H; Wang S; Ding X; Zhou C; Zhang X
Front Pharmacol; 2022; 13():1036208. PubMed ID: 36467060
[No Abstract] [Full Text] [Related]
9. Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening.
Zhu W; Xu M; Chen CZ; Guo H; Shen M; Hu X; Shinn P; Klumpp-Thomas C; Michael SG; Zheng W
ACS Pharmacol Transl Sci; 2020 Oct; 3(5):1008-1016. PubMed ID: 33062953
[TBL] [Abstract][Full Text] [Related]
10. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.
Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265
[TBL] [Abstract][Full Text] [Related]
11. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M
J A; Francis D; C S S; K G A; C S; Variyar EJ
J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185
[TBL] [Abstract][Full Text] [Related]
12. Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor.
Tan H; Ma C; Wang J
Med Chem Res; 2022; 31(7):1147-1153. PubMed ID: 35578732
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug.
Wang YC; Yang WH; Yang CS; Hou MH; Tsai CL; Chou YZ; Hung MC; Chen Y
Am J Cancer Res; 2020; 10(8):2535-2545. PubMed ID: 32905393
[TBL] [Abstract][Full Text] [Related]
14. Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M
Sacco MD; Ma C; Lagarias P; Gao A; Townsend JA; Meng X; Dube P; Zhang X; Hu Y; Kitamura N; Hurst B; Tarbet B; Marty MT; Kolocouris A; Xiang Y; Chen Y; Wang J
Sci Adv; 2020 Dec; 6(50):. PubMed ID: 33158912
[TBL] [Abstract][Full Text] [Related]
15. Pre-Steady-State Kinetics of the SARS-CoV-2 Main Protease as a Powerful Tool for Antiviral Drug Discovery.
Zakharova MY; Kuznetsova AA; Uvarova VI; Fomina AD; Kozlovskaya LI; Kaliberda EN; Kurbatskaia IN; Smirnov IV; Bulygin AA; Knorre VD; Fedorova OS; Varnek A; Osolodkin DI; Ishmukhametov AA; Egorov AM; Gabibov AG; Kuznetsov NA
Front Pharmacol; 2021; 12():773198. PubMed ID: 34938188
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic Insights into SARS-CoV-2 Main Protease Inhibition Reveals Hotspot Residues.
Marimuthu P; Gorle S; Karnati KR
J Chem Inf Model; 2021 Dec; 61(12):6053-6065. PubMed ID: 34842417
[TBL] [Abstract][Full Text] [Related]
17. Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors.
Ma C; Hu Y; Townsend JA; Lagarias PI; Marty MT; Kolocouris A; Wang J
bioRxiv; 2020 Sep; ():. PubMed ID: 32995786
[TBL] [Abstract][Full Text] [Related]
18. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel inhibitor of SARS-CoV-2 3CL-PRO through virtual screening and molecular dynamics simulation.
Bepari AK; Reza HM
PeerJ; 2021; 9():e11261. PubMed ID: 33954055
[TBL] [Abstract][Full Text] [Related]
20. Naturally occurring anthraquinones as potential inhibitors of SARS-CoV-2 main protease: an integrated computational study.
Das S; Singh A; Samanta SK; Singha Roy A
Biologia (Bratisl); 2022; 77(4):1121-1134. PubMed ID: 35034970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
